Trending...
- PUSHERMAN- – Best Feature Documentary Official Winner at NYC and London Festivals
- Chicago: Mayor Johnson Announces $411M Investment into Community Wealth-Building
- Fourteen-Year-Old Naperville Juvenile Charged with Possession of Loaded Semi-automatic Handgun
CHICAGO, June 22, 2025 ~ A new dual agonist, CagriSema, has shown promising results in improving weight loss for patients with and without type 2 diabetes who have overweight or obesity. The findings were presented at the 85th Scientific Sessions of the American Diabetes Association® (ADA) in Chicago and simultaneously published in the New England Journal of Medicine.
According to recent studies, nearly 90% of adults in the United States who have diabetes also have overweight or obesity. This highlights the strong connection between excess weight and the development or progression of type 2 diabetes. While there have been advancements in treatment options for obesity and type 2 diabetes with glucagon-like peptide-1 (GLP-1) receptor agonists, there is still a need for therapies that can address both weight and glucose management simultaneously.
CagriSema, a dual agonist that targets both appetite control and glucose regulation, aims to fill this gap. The drug is a once-weekly combination of semaglutide and cagrilintide, two weight-loss medications.
More on illi News
The effectiveness and safety of CagriSema were evaluated in two phase 3 studies known as REDEFINE 1 and REDEFINE 2. REDEFINE 1 included 3,400 adults without diabetes but with at least one weight-related health condition such as high blood pressure or heart disease. Participants were randomly assigned to receive CagriSema, semaglutide, cagrilintide, or placebo. On the other hand, REDEFINE 2 enrolled 1,200 adults with type 2 diabetes who received either CagriSema or placebo.
Both studies met their goals by demonstrating significant weight loss with once-weekly CagriSema compared to placebo. In REDEFINE 1, participants lost an average of 20.4% of their body weight at week 68 with CagriSema compared to only 3% with placebo. When considering full treatment adherence, weight loss with CagriSema increased to 22.7%, and 40.4% of participants achieved at least 25% weight loss. Similarly, in REDEFINE 2, participants lost an average of 13.7% of their body weight at week 68 with CagriSema compared to only 3.4% with placebo. When accounting for all study participants who adhered to treatment, weight loss with CagriSema rose to 15.7%, while only 3.1% was seen in the placebo group.
More on illi News
The safety profile of CagriSema was consistent with other GLP-1 receptor agonists, with mild-to-moderate gastrointestinal issues being the most common side effects.
Professor Melanie Davies from the University of Leicester commented on the findings, stating that they represent a significant step forward in expanding treatment options for people living with obesity and type 2 diabetes. She emphasized the importance of developing therapies that not only promote meaningful weight loss but also improve glucose control, giving patients more tools to manage their health effectively.
The researchers involved in this study note that it is part of a larger REDEFINE program that aims to evaluate the effectiveness of CagriSema across different populations and inform future regulatory submissions.
The findings were presented by Professor Davies and Dr. Timothy Garvey at a symposium during the ADA's Scientific Sessions on June 22nd at 8:00 a.m CT. The presentation focused on the efficacy and safety of CagriSema in adults with overweight or obesity based on data from REDEFINE 1 and REDEFINE 2 clinical trials.
According to recent studies, nearly 90% of adults in the United States who have diabetes also have overweight or obesity. This highlights the strong connection between excess weight and the development or progression of type 2 diabetes. While there have been advancements in treatment options for obesity and type 2 diabetes with glucagon-like peptide-1 (GLP-1) receptor agonists, there is still a need for therapies that can address both weight and glucose management simultaneously.
CagriSema, a dual agonist that targets both appetite control and glucose regulation, aims to fill this gap. The drug is a once-weekly combination of semaglutide and cagrilintide, two weight-loss medications.
More on illi News
- Norman Bolden to Debut "Norman's Bistro on the Lake" Rainbow Beach - Ribbon Cutting Ceremony Today
- Red Carpet Screening of "Ghosted" Featuring Landon Brittain at the Samuel Goldwyn Theatre
- Stem Cell-Derived Islet Therapies Shown to Reduce the Need for Injectable Insulin
- Sploot Veterinary Care Brings Modern Pet Care to Forest Park with New Clinic Opening June 23, 2025
- Anti-war groups protest vs US-NATO actions in Gaza, Iran, the Global South
The effectiveness and safety of CagriSema were evaluated in two phase 3 studies known as REDEFINE 1 and REDEFINE 2. REDEFINE 1 included 3,400 adults without diabetes but with at least one weight-related health condition such as high blood pressure or heart disease. Participants were randomly assigned to receive CagriSema, semaglutide, cagrilintide, or placebo. On the other hand, REDEFINE 2 enrolled 1,200 adults with type 2 diabetes who received either CagriSema or placebo.
Both studies met their goals by demonstrating significant weight loss with once-weekly CagriSema compared to placebo. In REDEFINE 1, participants lost an average of 20.4% of their body weight at week 68 with CagriSema compared to only 3% with placebo. When considering full treatment adherence, weight loss with CagriSema increased to 22.7%, and 40.4% of participants achieved at least 25% weight loss. Similarly, in REDEFINE 2, participants lost an average of 13.7% of their body weight at week 68 with CagriSema compared to only 3.4% with placebo. When accounting for all study participants who adhered to treatment, weight loss with CagriSema rose to 15.7%, while only 3.1% was seen in the placebo group.
More on illi News
- Dr. Jacqueline West Honored as Best Dentist in JAX by Folio Weekly
- Naperville Police Investigate Fatal Traffic Crash at Chicago Avenue and Naper Boulevard
- The American Diabetes Association Demonstrates Its Commitment to Curbing the Obesity Epidemic with Obesity Standards of Care
- Exciting News: Pivotal Health Solutions Acquires Revolutionary Portable Parallel Bars
- Miboxer Achieved New Goal in GILE 2025
The safety profile of CagriSema was consistent with other GLP-1 receptor agonists, with mild-to-moderate gastrointestinal issues being the most common side effects.
Professor Melanie Davies from the University of Leicester commented on the findings, stating that they represent a significant step forward in expanding treatment options for people living with obesity and type 2 diabetes. She emphasized the importance of developing therapies that not only promote meaningful weight loss but also improve glucose control, giving patients more tools to manage their health effectively.
The researchers involved in this study note that it is part of a larger REDEFINE program that aims to evaluate the effectiveness of CagriSema across different populations and inform future regulatory submissions.
The findings were presented by Professor Davies and Dr. Timothy Garvey at a symposium during the ADA's Scientific Sessions on June 22nd at 8:00 a.m CT. The presentation focused on the efficacy and safety of CagriSema in adults with overweight or obesity based on data from REDEFINE 1 and REDEFINE 2 clinical trials.
Filed Under: Business
0 Comments
Latest on illi News
- DOT Miners launches a new cloud mining platform: low threshold, high transparency, and helps promote the inclusion of global digital assets
- Fray Fitness and Truemed Partner to Enable HSA/FSA-Funded Fitness Equipment Purchases
- Crazy Discount Codes App Transforms Mobile Shopping With Real-Time Deals
- KPC Marketing Services Launches to Revolutionize Legal Marketing for Small and Mid-Sized Law Firms
- Sploot Vets and DeepScan Launch Exclusive Regional U.S. Partnership to Bring Breakthrough Pet DNA Test to Market
- Lifeway Foods Toasts to 40 Years of Kefir with a Celebratory Drone Show in Chicago
- Naperville: Court Grants State's Motion to Deny Pre-Trial Release for Elgin Man Accused of Attempt Murder
- Various Measures Introduced to and Approved by The Chicago City Council
- As Sober.Buzz Community Explodes It's Growth Globally it is Announcing "Spreading the Good BUZZ" Podcast Hosted by Josh Case Debuting July 7th
- Grok3 Ranks BWRCI's Quantum-Secured AI Fail-Safe Protocol Among Most Novel AI Safety Systems
- Coming Soon: The Cottages at Powell Park Offer a Rare Blend of Charm, Convenience, and Community in Raleigh
- CredHub and All County Property Management Franchise Corp. Partner to Empower Franchisees with Rental Payment Credit Reporting Solutions
- Pregis Shares 2024 Sustainability Report Highlighting Progress in Circular Product Innovation, Emissions Accountability, and Global Impact
- Initial Order Received from Vietnamese Maritime Security and Defense Services for Advanced Video Compression Solution: RMX; Stock Symbol: RMXI
- Keebos Launches New Universal Pearl Strap That Attaches to Any Phone Case
- Anova Launches Fastest CME to London Service for Financial Markets
- Nola Blue Records signs Mud Morganfield
- Work 365 Launches Certified Provider Integration (CPI) Program to Help Distributors and CSPs Navigate Microsoft's Evolving Ecosystem
- Five Aster Awards! Fusion Marketing Group Brings Home Big Wins in 2025!
- Plot Thickens: Carvana (CVNA) says my Luxe SUV CARVANA CERTIFIED Failure Car They Sold Me "Price Just Went Up!" BUYERS BEWARE - DAY 18